Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people taking Wegovy begin to notice weight loss within the first four to eight weeks, though the clearest results build over months, not days. In the STEP 1 clinical trial, participants lost an average of around 15% of their body weight over 68 weeks at the 2.4 mg maintenance dose — a figure that reflects a gradual, escalating process tied closely to the titration schedule. Wegovy is a prescription-only medicine; a clinical assessment by a registered prescriber determines whether it is suitable for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first Wegovy pen contains the 0.25 mg starting dose. This is a tolerability step; its job is to let your digestive system adjust before the dose climbs. Some people see a small dip on the scales in these early weeks, often from reduced appetite and fluid shifts rather than meaningful fat loss. Others see very little movement at all. Neither is a sign that the medicine is or isn't working.
Side effects (nausea, mild stomach discomfort, loose stools) are most common here. They tend to ease as the body settles. Eating smaller portions of bland, lower-fat food in this period helps most people through. The NHS semaglutide patient information page has practical guidance on managing these early symptoms.
One thing worth knowing: Wegovy arrives in a pre-filled pen, tracked to your door by DPD in plain, unbranded packaging. Each pen lasts four weeks. The cadence of treatment is built into the product itself, which makes it easier to follow the schedule your prescriber sets.
From the second pen onwards, the dose steps up) typically through 0.5 mg, then 1.0 mg, and appetite suppression becomes noticeably stronger for most people. This is usually when weight loss becomes more consistent week to week. If you are curious about how long before you see weight loss on Wegovy, a reduction of roughly 5% of starting body weight by the end of month three is a reasonable benchmark for many, though individual variation is real.
If you are asking how long on Wegovy before seeing results in a way you can actually measure, months two to four are generally where that answer lives. The appetite change tends to feel different too: not just eating less, but genuinely wanting less. People often describe forgetting to finish a meal they would previously have finished without thinking.
This is also when lifestyle habits compound the medicine's effect. Wegovy works alongside a reduced-calorie diet and increased activity, the clinical trials were designed that way. Protein intake and staying well-hydrated matter particularly at this stage, as rapid appetite suppression can make it easy to under-eat without realising.
The standard Wegovy maintenance dose is 2.4 mg. Most people reach it around month five of treatment, after stepping through 1.7 mg. It is only once someone has been stable on that maintenance dose for several weeks that the full effect of the medicine is established. This is why the question of how long Wegovy takes to work cannot honestly be answered with a single number.
The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults without diabetes over 68 weeks. At the end of the trial, the semaglutide 2.4 mg group had lost an average of around 15% of body weight versus roughly 2.4% in the placebo group. That headline figure is a 68-week number; it does not describe month two. If you want a fuller picture of how long before you see results from Wegovy at each stage of the dose escalation, understanding the timeline helps set expectations that are actually achievable.
For those asking about the average weight loss on Wegovy across the full trial period, that 15% average is the most cited and most reliable figure. Some participants lost considerably more; others less. The range is wide, and the prescriber's role is to help you interpret your own progress rather than compare yourself to a headline.
A plateau (a period where the scale stops moving) is normal, particularly when the dose has just changed. The body adjusts. What matters is the trend over weeks, not the number on a single morning.
If you are six months in at your maintenance dose and have lost less than 5% of your starting weight, NICE's guidance on semaglutide recommends reviewing whether to continue. That conversation belongs with your prescriber, who can assess whether the dose, lifestyle factors, or something else needs attention. Our frequently asked questions cover several scenarios where this comes up.
A couple of things that genuinely slow results: not titrating as prescribed (staying on a lower dose for longer than planned); significant under-eating that causes muscle loss rather than fat loss; and GI side effects severe enough to affect food intake unpredictably. All of these are worth flagging to a prescriber rather than managing alone. You can read more about how long it typically takes to see results on Wegovy across the treatment period or explore the broader range of weight-loss treatment options if you are still deciding which approach fits your situation.
If you would like a clinician to review your suitability and talk through what a realistic timeline might look like for you specifically, start your free consultation with our prescribers today.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.